Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296125 · ClinicalTrials.gov registry record · Phase 3
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 674
- Enrollment target
NCT02296125 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 674 participants.
The verdict
NCT02296125, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 674 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
Interventions
- DRUG AZD9291 80 mg/40 mg + placebo
- DRUG Placebo Erlotinib 150/100mg
- DRUG Placebo Gefitinib 250 mg
- DRUG Erlotinib 150/100 mg
- DRUG Gefitinib 250 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 674 participants |
| Start Date | 2014-12-03 |
| Est. Completion | 2025-11-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02296125
The ClinicalTrials.gov registry entry for NCT02296125 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 674 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which AZD9291 80 mg/40 mg + placebo is the first listed.
NCT02296125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02296125 about?
NCT02296125 is a clinical study titled "AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer". To assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
What is the current status of trial NCT02296125?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 674 participants. The study started on 2014-12-03. Estimated completion is 2025-11-20.
What interventions are being tested in trial NCT02296125?
The interventions under investigation include: AZD9291 80 mg/40 mg + placebo (DRUG), Placebo Erlotinib 150/100mg (DRUG), Placebo Gefitinib 250 mg (DRUG), Erlotinib 150/100 mg (DRUG), Gefitinib 250 mg (DRUG).
Who is sponsoring clinical trial NCT02296125?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.